STIPE Therapeutics ApS: Financial statements 2022
CVR: 39691175
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
STIPE Therapeutics ApS (CVR 39691175) has filed annual accounts for 2022. In 2022, the company reported a gross profit of EUR -6,587,704 and a net result of EUR -8,272,781 compared with EUR -5,485,392 the year before. Equity in the 2022 report amounted to EUR 1,959,107. The solvency ratio was 31.6%. The company had 16 employees in the financial year.
- Gross Profit
- EUR -6,587,704
- Profit/Loss
- EUR -8,272,781
- Equity
- EUR 1,959,107
- Total Assets
- EUR 6,201,832
- Employees
- 16
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | -6.6 mio. EUR | -8.3 mio. EUR | 2 mio. EUR | 16 |
| 2021 | - | -4.1 mio. EUR | -5.5 mio. EUR | 10.2 mio. EUR | 16 |
| 2020 | - | -2.9 mio. EUR | -3.9 mio. EUR | 3.8 mio. EUR | 14 |
Official annual report
Keep an eye on STIPE Therapeutics ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
STIPE Therapeutics ApS has published its annual report for 2021. Gross profit came to DKK -4,086,580, and the net result was DKK -5,485,392.
About STIPE Therapeutics ApS
STIPE Therapeutics ApS is a Danish company of the type Anpartsselskab based in København V, founded in 2018. The company is under bankruptcy. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company's owners include CLAUS OLESEN HOLDING ApS, Novo Holdings A/S and Sunstone Life Science Ventures Fund IV K/S. The company has 5 employees (2018). In 2024, the company reported a gross profit of EUR -842,285 and a net result of EUR 1,448,748 compared with EUR -4,456,130 the year before. Equity in the 2024 report amounted to EUR 1,087,512.